Sublingual Immunotherapy

Glycerin: The Ideal Diluent for Sublingual Immunotherapy Allergy Drops

By Kaley JacobsonUpdated 2 minutes

Using the La Crosse Method™ Protocol at Allergychoices, we believe that a critical point of under the tongue delivery of the antigens for sublingual immunotherapy is the vehicle in which the antigens are suspended. Our nearly 45 year history with custom sublingual immunotherapy allergy drops, along with more than 300,000 patients and billions of treatment doses, has pointed to glycerin as the diluent of choice.

The physical stability of glycerin at a 50% concentration preserves the structure and biological activity of the allergens at room temperature. Glycerin is an ideal diluent for mixed allergens and allergenic products for treatment of allergic disease. With a slightly sweet taste, the drop experience is pleasant and easy for all ages. We have found that this mixture keeps the extracts stable for the defined prescription duration at room temp, easily allowing allergic patients to continue their sublingual immunotherapy treatment wherever they are – home, work or traveling in all sorts of occupations from children at home to the far reaches of military deployment; an ideal solution for allergy treatment.

This is part 3 of a 3 part series on the Key Tenets of the La Crosse Method Practice Protocol.

Author: Mike Kachel, RPh, Allergychoices Pharmacy Director

References

  1. Passalaqua, G., Compalati, E., Canonica, G.W. Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organization Journal 2010 Jul;3(7):216-219.
  2. Theodoropoulos, D., Morris, M., Morris, D. Emerging Concepts of Sublingual Immunotherapy for Allergy. Drugs of Today 2009, 45(10):737-750.
  3. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Annals of Allergy, Asthma & Immunology 2006, 97:158-163.
  4. Bagnasco, M., Mariani, G., Passalacqua, G., et al. Absorption and distribution kinetics of the major Paretaria judaica allergen(Par j 1) administered by noninjectable routes in healthy human beings. Journal of Allergy and Clinical Immunology 1997 July;100(1):122-129.
  5. Cox, L., Li, J.T., Nelson, H., et al. Allergen Immunotherapy: a practice parameter second update. Journal of Allergy & Clinical Immunology. 2007 Sep;120(3Suppl):S25-85.

Keep reading

Related articles

All articles
  • 3 minutes

    4 Allergy Terms Explained

    Allergy care can feel like a lot at first — new terms, new treatments, and new information all at once. Below is a simple explanation of four common terms you’ll likely hear at your first allergy appointment. If anything isn’t clear, your provider is always the best resource for questions. Histamine You’re sure to have…

  • 3 minutes

    Prepping for Spring Allergies

    Spring allergy season brings weeks of sneezing, congestion, and discomfort for hundreds of thousands across the country. By preparing your body, your home, and your treatment plan, you can minimize exposure and seasonal allergies symptoms. Taking a proactive approach – as soon as today – can significantly reduce symptoms before they spiral. Start Antihistamines Before…

  • 3 minutes

    The Allergy Domino Effect: How Minor Symptoms Lead to Major Employer Costs

    Leaving allergies untreated is like tipping the first domino – what may start as seasonal sniffling can turn into long term, comorbid conditions. Sinusitis, asthma, migraines, digestive issues, mental health conditions, and more, can all stem from an underlying allergy. From an employer’s perspective, that’s years and years of healthcare costs, all pointing back to…

Next step

Ready to treat the cause of your allergies?

Allergychoices connects patients and providers with personalized sublingual immunotherapy.